Balyasny Asset Management LLC Lipocine Inc. Transaction History

Balyasny Asset Management LLC

  • $58 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2018

Aug 14, 2018
SELL
$1.06 - $1.78 $39,304 - $66,002
-37,080 Closed
0 $0
Q1 2018

May 15, 2018
SELL
$1.18 - $3.46 $62,445 - $183,103
-52,920 Reduced 58.8%
37,080 $57,000
Q4 2017

Feb 14, 2018
BUY
$3.36 - $4.35 $302,400 - $391,499
90,000
90,000 $310,000

About Lipocine Inc.

LPCN Quotes by TradingView
  • Ticker LPCN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 88,510,800
  • Market Cap $468M
  • Description
  • Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone rep...
More about LPCN
Track This Portfolio

Track Balyasny Asset Management LLC Portfolio

Follow Balyasny Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email